Hui Yufei, Jiao Xue, Yang Li, Lu Dejin, Han Yanbo, Yang Wen, Cao Yanli, Miao Yuxi, Gong Shiqiang, Wei Minjie
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Acta Pharm Sin B. 2025 Jul;15(7):3404-3418. doi: 10.1016/j.apsb.2025.04.022. Epub 2025 Apr 26.
Mesenchymal stem cells (MSCs) have been widely used in the treatment of various autoimmune and inflammation-related diseases due to their potent immunomodulatory properties. Several studies have demonstrated that MSC-mediated immunomodulation is complex and bidirectional, with the microenvironment influencing the direction of this modulation. Indoleamine-2,3-dioxygenase (IDO), an immunosuppressive factor, has been identified as a key "switch" in the immunomodulatory role of MSCs. In this review, we explore how IDO functions as a critical regulator of MSC immunoregulatory plasticity. We delve into the mechanisms by which changes in IDO expression affect the function of various immune cells, summarize relevant research and clinical advances regarding the role of IDO expression in MSC-based therapies for various diseases, and discuss potential therapeutic strategies that target IDO to enhance the stability of MSC therapeutic effects. This provides a theoretical foundation for optimizing MSCs as safer and more effective clinical therapeutic agents.
间充质干细胞（MSCs）因其强大的免疫调节特性而被广泛应用于各种自身免疫性疾病和炎症相关疾病的治疗。多项研究表明，MSC介导的免疫调节是复杂且双向的，其微环境会影响这种调节的方向。吲哚胺-2,3-双加氧酶（IDO）作为一种免疫抑制因子，已被确定为MSCs免疫调节作用中的关键“开关”。在本综述中，我们探讨了IDO如何作为MSC免疫调节可塑性的关键调节因子发挥作用。我们深入研究了IDO表达变化影响各种免疫细胞功能的机制，总结了关于IDO表达在基于MSC的各种疾病治疗中的作用的相关研究和临床进展，并讨论了靶向IDO以增强MSC治疗效果稳定性的潜在治疗策略。这为优化MSCs作为更安全、更有效的临床治疗药物提供了理论基础。
